Aaron Boster is Ace


I’m part of the Aaron Boster fanclub.

He is an American neurologist who inhabits the social media space.

In this video he asks questions of the old school (dinosaur) and new school neurologist……. Love it and he has three shirts… although two sound like the same one:-)

Sadly there are plenty of the “old school” neurologists about. They should carry a health warning or is that Ill-Health warning?

Some are where you would least expect them!!!!!.

Which you would you rather see?

Sadly the accents I hear from the old school neuro are rather different to the ones that Neuro Boster makes, plum up backside for some and others …..I hear “well well .,. we’ll get you a nice wheelchair.” 🙁

If it wasn’t so sad it would be funny….Keep up the good work Aaron

About the author



  • How does one go about getting brain volume tracked? He makes it sound like the old neurologist is just ticking the wrong box on a form, but I was under the impression that it is only available to a handful of people as part of cutting edge research?

  • Not so enthralled, personally. There are no drugs for progression in terms of neuroprotection. Or repair. For PPMS without relapse activity.

      • I’m not blaming the messenger, but the message.

        There are no proven neuroprotective drugs _available_ at this time.

        • Wrong I’m sorry to say. All current DMT are neuroprotective in the sense that the inflammatory response is causing neurodegeneration. The biggest inhibitor of neurofilament release into the blood are the current DMT.

          • Yes yes yes…

            But they are not effective for inactive disease, PPMS. There is nothing available for my presentation of MS.

          • Yes Yes Yes and maybe no no no. If the therapeutic lag idea of profG is right, which it may not be…then it may not be correct that ocrelizumab does not work for your disease.

            The natalizumb study indicated it neeed about 3 years for the benefit to show itself by which time it is written off as no use by many.

            However, Next up I totally agree with you that that we need more than the immunosuppressive and here I wonder if the new school is split is to new new school and the non-thinking new school, because the biology indicates that combinations are the way to go. Yet, time and time again we see monotherapy (one drug) trials.

            I get exhausted banging this drum. I should have an arm like a fiddler crab as I have been banging-on so long. It is very frustrating however that this approach is not being properly tested.

          • Wouldn’t it have been good to have trialled ocrelizumab in “inactive” PPMS then? Why was the trial filled with likely responders? Then we wouldn’t still be invoking hopeful theories, and people with my sort of disease presentation and age bracket would have some basis for a decision as to whether the potentially serious side effects of ocrelizumab are worth risking. The tough questions don’t get answered. I too feel frustrated, and fobbed off. For various reasons, I’m in no position to take part in any trial and so I am putting everything into diet and exercise, and just getting on with the cards I’ve been dealt, remembering the many things there are to be thankful for.

          • I can understand your frustration, I am likewise frustrated. However to address your point if you want to get a positive, knowing that younger people and people with active disease responded to rituximab, then you would surely load your study with people that could response. That is what they did and Result = ocrelizumab is approved for PPMS (in US). You have to learn from past mistakes. In europe they didn’t get away with this. Now you are making money, you may risk the more difficult task of looking at “inactive” if there is such a thing as essentially 100% of people at post-mortem have active lesions. Don’t load your trial with likely responders and pick the wrong endpoint and you have nothing and you kill off the basic science in the process. If the right endpoints had been selected for the trials, progressive would have had a DMT over ten years ago and by now we would have been adding neuroprotectives in a mix. I now this is disappointing. The academic groups are trying in more ways than I am allowed to say at the moment, but if you live in the UK this may change and remember if you are eligiable you can sign up to the MS STAT 2 trial

    • We don’t have the monoply of ideas but if he presents the arguments in an engaging way and helps people think about their choices then it doesn’t matter. It is amazing the number of times you say things to people and they don’t get it. The difference between a 40 watter and a fairy light with dimmer switch.
      This is a term used by MD2 to describe a well known old school neuro. It was based on the amount.of time you had to say stuff before the lights come on in people’s head.

      • Indeed, it does not matter where he gets his information (this blog is a great source). I like his attitude and I think he does an amazing job at informing regular people (let’s be honest, many of the blog-posts here probably go over the heads of many patients).
        It is great that people like Aaron take the time to inform regular patients about everything MS related, based on science and thoroughly, but not too complicated.

          • Haha, no as a PhD I love them, keep up the great work!

            I just think that is brilliant that a non-dinosaur like Aaron is posting video’s that are understandable for everybody.

        • Bram, you will be surprised how knowledgeable many pwMS are about MS, especially after having MS for several years.
          I myself have an MRes Research degree in the subject of MS.

      • That’s true. On MS social channels here in the US, MSers are just starting to talk about brain atrophy. And that’s probably because of Boster videos.

        • I bet Aaron hasn’t done a video on the merits of what brain atrophy is. I am not a fan as it is not fit for purpose because of pseudo atrophy

  • Aaron Boster is fabulous, a light in the darkness–as is this blog. Please never underestimate what this place does for so many of us.

By MouseDoctor



Recent Posts

Recent Comments